Overview of Our Drug CandidatesOur current drug candidates are summarized below. AML caused an estimated 11,180 deaths in 2020 in the United States. This phenomenon is now known as environment-mediated drug resistance, or EMDR. The trial consisted of two parts. We are developing, GMI-1359, that simultaneously targets both E-selectin and CXCR4. An SPA, however, does not guarantee that a trial will be successful. The FDA may request additional information rather than accept an NDA for filing. We may explore some of these opportunities for our product candidates as appropriate. Our other drug candidates are still in preclinical development. A failure of one or more clinical trials can occur at any stage of development. Obtaining and maintaining adequate reimbursement for our drugs may be difficult. We do not believe that we can obtain patent protection for our platform. We generally contract with third parties for the disposal of these materials and wastes. We and our collaborators are exposed to the risk of employee fraud or other misconduct. The trading price of our common stock has been and is likely to continue to be volatile.
